Cargando…

The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer’s disease

INTRODUCTION: Souvenaid® containing Fortasyn® Connect is a medical food designed to support synapse synthesis in persons with Alzheimer’s disease (AD). Fortasyn Connect includes precursors (uridine monophosphate; choline; phospholipids; eicosapentaenoic acid; docosahexaenoic acid) and cofactors (vit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shah, Raj C, Kamphuis, Patrick J, Leurgans, Sue, Swinkels, Sophie H, Sadowsky, Carl H, Bongers, Anke, Rappaport, Stephen A, Quinn, Joseph F, Wieggers, Rico L, Scheltens, Philip, Bennett, David A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978853/ https://www.ncbi.nlm.nih.gov/pubmed/24280255 http://dx.doi.org/10.1186/alzrt224

Ejemplares similares

The Effect of Souvenaid on Functional Brain Network Organisation in Patients with Mild Alzheimer’s Disease: A Randomised Controlled Study
por: de Waal, Hanneke, et al.
Publicado: (2014)

Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer’s disease
por: Rijpma, Anne, et al.
Publicado: (2015)

Effect Size Analyses of Souvenaid in Patients with Alzheimer’s Disease
por: Cummings, Jeffrey, et al.
Publicado: (2016)

Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2019)

Efficacy of Souvenaid(®) Combined with Acetylcholinesterase Inhibitors in the Treatment of Mild Alzheimer’s Disease
por: García-Alberca, José María, et al.
Publicado: (2023)

Souvenaid in the management of mild cognitive impairment: an expert consensus opinion
por: Cummings, Jeffrey, et al.
Publicado: (2019)

Design of the NL-ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2016)

Economic evaluation of supplementing the diet with Souvenaid in patients with prodromal Alzheimer’s disease
por: Mar, Javier, et al.
Publicado: (2020)

Budget impact analysis of the use of Souvenaid in patients with prodromal Alzheimer’s Disease in Spain
por: Mar, Javier, et al.
Publicado: (2022)

The medical food Souvenaid affects brain phospholipid metabolism in mild Alzheimer’s disease: results from a randomized controlled trial
por: Rijpma, Anne, et al.
Publicado: (2017)

Assessment of a Potential Synergistic Effect of Souvenaid(®) in Mild Alzheimer’s Disease Patients on Treatment with Acetylcholinesterase Inhibitors: An Observational, Non-Interventional Study
por: Viñuela, Félix, et al.
Publicado: (2021)

Mild Cognitive Impairment with a High Risk of Progression to Alzheimer’s Disease Dementia (MCI-HR-AD): Effect of Souvenaid(®) Treatment on Cognition and (18)F-FDG PET Scans
por: Manzano Palomo, Maria Sagrario, et al.
Publicado: (2019)

Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer’s Disease
por: Hüll, Michael, et al.
Publicado: (2017)

Neuropsychiatric symptoms in Brazilians with mild cognitive impairment and dementia
por: Wilson, Robert S., et al.
Publicado: (2021)

Ventilatory response to exercise in adolescents with cystic fibrosis and mild-to-moderate airway obstruction
por: Bongers, Bart C, et al.
Publicado: (2014)

Reply to “Neuropsychiatric symptoms in community‐dwelling older Brazilians with mild cognitive impairment and dementia”
por: Wilson, Robert S., et al.
Publicado: (2022)

Alzheimer’s disease frequency peaks in the tenth decade and is lower afterwards
por: Farfel, Jose M., et al.
Publicado: (2019)

Compensatory striatal–cerebellar connectivity in mild–moderate Parkinson's disease
por: Simioni, Alison C., et al.
Publicado: (2015)

Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
por: Vandenberghe, Rik, et al.
Publicado: (2016)

Association of total daily physical activity with disability in community-dwelling older persons: a prospective cohort study
por: Shah, Raj C, et al.
Publicado: (2012)

White matter hyperintensities, incident mild cognitive impairment, and cognitive decline in old age
por: Boyle, Patricia A., et al.
Publicado: (2016)

Association of Heel Bone Mineral Density With Incident Disability and Mortality in Community‐Dwelling Older Adults
por: Ross, Ryan D, et al.
Publicado: (2020)

Characteristics of falls in mild and moderate Alzheimer’s disease
por: Kato-Narita, Eliane Mayumi, et al.
Publicado: (2009)

Effect of TTP488 in patients with mild to moderate Alzheimer’s disease
por: Burstein, Aaron H, et al.
Publicado: (2014)

Cognitive decline and hippocampal functional connectivity within older Black adults
por: Han, S. Duke, et al.
Publicado: (2022)

Relation of Cerebral Vessel Disease to Alzheimer’s Disease Dementia and Cognitive Function in Older Persons: A Cross-sectional Study
por: Arvanitakis, Zoe, et al.
Publicado: (2016)

The conceptual relevance of assessment measures in patients with mild/mild-moderate Alzheimer's disease
por: Hartry, Ann, et al.
Publicado: (2018)

TDP-43 pathology in anterior temporal pole cortex in aging and Alzheimer’s disease
por: Nag, Sukriti, et al.
Publicado: (2018)

Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease
por: Seltzer, Ben
Publicado: (2010)

Neuropsychological Rehabilitation in Mild and Moderate Alzheimer’s Disease Patients
por: Ávila, Renata, et al.
Publicado: (2007)

Altered Resting State Cortico-Striatal Connectivity in Mild to Moderate Stage Parkinson's Disease
por: Kwak, Youngbin, et al.
Publicado: (2010)

Estimating attrition in mild-to-moderate Alzheimer’s disease and mild cognitive impairment clinical trials
por: Ritchie, Marina, et al.
Publicado: (2023)

Modulation of Brain Activity and Functional Connectivity by Acupuncture Combined With Donepezil on Mild-to-Moderate Alzheimer's Disease: A Neuroimaging Pilot Study
por: Zhan, Yijun, et al.
Publicado: (2022)

Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy
por: Landen, Jaren W., et al.
Publicado: (2017)

Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease
por: Ballard, Clive, et al.
Publicado: (2019)

Dysphagia is closely related to frailty in mild-to-moderate Alzheimer’s disease
por: Güner, Merve, et al.
Publicado: (2023)

Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine
por: Schmidt, R, et al.
Publicado: (2008)

Transcranial direct current stimulation modulates working memory and prefrontal-insula connectivity after mild-moderate traumatic brain injury
por: Quinn, Davin K., et al.
Publicado: (2022)

Systemic brain derived neurotrophic factor but not intestinal barrier integrity is associated with cognitive decline and incident Alzheimer’s disease
por: Voigt, Robin M., et al.
Publicado: (2021)

Modifiable psychosocial risk factors and delayed onset of dementia in older populations: analysis of two prospective US cohorts
por: Grodstein, Francine, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_95ug33lkacturu8ksv01a9ssag